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The Editorial on the Research Topic
HIV and Illicit Drugs of Abuse
Drugs of abuse plays a major role in increasing the risk of HIV transmission, disease progression,
and less adherence to the antiretroviral therapy, which significantly contribute for morbidity
and mortality of the HIV infected patients (Anthony et al., 1991; Arnsten et al., 2002). While
injection drug use is the second most common route for the HIV transmission, alcohol
consumption, smoking, inhaling, and ingesting drugs such as heroin, morphine, crack cocaine,
methamphetamine (METH) will increase the risk for obtaining HIV infection (Friedland and
Vlahov, 2011). Heroin is the most commonly used illicit drug in HIV patients followed by
stimulants such as cocaine and METH (AIDSinfo, 2012). Drug abuse is one of the risk factors
for severe neurocognitive dysfunctions in HIV-positive individuals (Nath et al., 2002). Therefore,
drugs of abuse and their role on inducing HIV pathogenesis/neuropathogenesis is an urgent need
to study for the development of potential therapeutics for HIV infected drug abuser. In this special
issue, Garin et al. reported that recreational drug use is higher in HIV infected persons than the
general population and cannabis is the highly used recreational drug in the Europe followed by
cocaine, amphetamines and ecstasy.
Opioid abuse increases the HIV disease progression by effecting host immune function,
promoting the virus entry into the immune cells and replication and it also causes severe
neurocognitive disorders by inducing the neuro-inflammation (Roy et al., 2011; Smith et al.,
2014). While gut microbiota helps in regulating immune homeostasis, both HIV and opioids
are known to disrupt gut homeostasis, gut immunity, and microbial translocation that may
lead to the accelerated HIV disease progression. In this context, Meng et al. reviewed the
mechanisms of opioid induced HIV disease progression by disrupting the gut homeostasis. As
pathological pain is more common in 50% of HIV/AIDS patients, HIV-infected opioid abusers
reported to show severe neuropathology than HIV-infected non-drug users (Bell et al., 1998, 2006;
Smith et al., 2014). Liu et al. reviewed potential mechanisms that induce neuropathic pain in
HIV and opioids interaction. While heroin has been reported to increase the HIV infection in
macrophages by inhibiting the HIV restriction miRNAs (miRNA-28, miRNA-125b, miRNA-150,
and miRNA-382), naltrexone (opioid-receptor antagonists) reported to recover the expression of
these miRNAs (Wang et al.). Also, Lan et al. discussed about the association of Apolipoprotein
L1 (APOL1) variants (G1 and G2 alleles) in Heroin-associated Nephropathy (HAN) and Human
Immunodeficiency Virus associated Nephropathy (HIVAN) in African Americans which opens an
interesting point to explore the onset of focal and segmental glomerulosclerosis (FSGS) in HIV
infected heroin abusers in African Americans. In the post-mortem brain tissues of HIV-infected
subjects with neurocognitive impairment (NCI) ± HIV encephalitis (HIVE), Dever et al. reported
the dysregulation of autophagy genes and proteins; and in in vitro, supernatant from HIV-1-
infected microglia/HIV-1 Tat protein in combination with morphine reported to alter autophagic
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activity and reduced dendrite length. Morphine in combination
with HIV-1 gp120 has been reported to increase oxidative stress,
DNA damage, and subsequently affecting cell cycle process
(Samikkannu et al.).
Cocaine is the second most commonly abusing drug in US
and cocaine abuse in HIV infected patients reported for rapid
progression to AIDS and are prone to develop severe form of
neurocognitive disorders (Avants et al., 1997; Baldwin et al., 1998;
Zenon et al., 2014). In this special issue, Bertrand et al. reported
that R-Equol, S-Equol (derivatives of the soy isoflavone, daidzein)
reduces the neurotoxic effects (reduced dendritic synapses) of
cocaine in combination with HIV-1 Tat in an estrogen receptor
beta dependent manner. Roy et al. reported the reduced levels
of DJ1 protein (a gene linked to autosomal recessive early-onset
Parkinson’s disease) and associated increased ROS production
in HIV exposed neuronal cells in combination with cocaine.
Also two comprehensive review articles focused on the effect
of cocaine abuse on HIV pathogenesis (Dash et al.) and role in
progression to HIV-1 associated neurocognitive disorders (Dahal
et al.).
In North America, methamphetamine is the widely used
recreational drug especially in men who have sex with men
(MSM) infected with HIV (Colfax and Shoptaw, 2005). In this
special issue, Bortell et al. reported that mononuclear cells
isolated from SIV infected METH treated brain has significantly
upregulated IL2RG and its ligand cytokine (IL15, IL15RA) levels
compared to the control and SIV alone infected animals which
can aggravate the neuroinflammation. Borgmann and Ghorpade
have contributed a comprehensive review on alterations in
astrocyte intrasignaling pathways, gene expression, and function
in the presence of HIV and its proteins in combination with
METH that contributes to the neuroinflammation and also
focused on the therapeutics for astroglial activation and function.
Mediouni et al. discussed about effect of METH and HIV-Tat on
the development of HAND.
Alcohol use disorder is more common in the United States
and in persons living with AIDS, rates of heavy drinking are even
higher than those in the general population (Petry, 1999). Heavy
alcohol consumption increases the risk of HIV transmission,
higher viral load and lower adherence to ART (Baum et al., 2010).
Agudelo et al. reported the higher HIV infectivity in alcohol
treated monocyte derived dendritic cells (MDDC) and also
observed differentially modulated HIV infection, altered MDDC
endocytic function and cytokine production in combination with
cannabinoids (THC and JWH-015).
In US, the prevalence of cigarette smoking range from
40 to 75% in HIV-infected individuals compared to 20% in
general population (Pacek and Cioe, 2015). Nicotine is the
active ingredient in tobacco and considered one of the most
addictive drugs of all time and reported to dysregulate synaptic
plasticity in HIV exposed neuronal cells (Atluri et al., 2014).
On the other hand, direct injection of HIV-Tat into rat intra
ventral tegmental area reported to attenuate nicotine-induced
behavioral sensitization (Zhu et al.). Rao and Kumar reviewed
the effect of smoking on HIV replication and role of polycyclic
aromatic hydrocarbons (PAH-important constituents of cigarette
smoking) and CYP1 enzymes (CYP1A1 and CYP1B1- activators
of PAH) in HIV pathogenesis. Chinnapaiyan and Unwalla
reviewed the mechanisms of mucociliary suppression in people
living with HIV who are smokers or illicit drug abusers.
Also, this special issue include review articles on epigenetic
alterations in drugs of abuse and HIV infection that affects
Vitamin D receptors (Chandel et al.); role of miRNs during
HIV infection and effect of drugs of abuse on the expression
of miRNAs and its effect on HIV associated neurocognitive
disorders (Pilakka-Kanthikeel and Nair); effect of HIV-1 Tat
and drugs of abuse during HIV infection and their role in
the development of NeuroAIDS (Maubert et al.); and anti-HIV
effects of different natural compounds (Kurapati et al.).
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